

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Confirmation No: 9837
)	
MEZAACHE, Naima, et al.)	Group Art Unit: 1656
)	
Application Number: 10/779,784)	Examiner: Monshipouri, Maryam
)	
Filed: February 18, 2004)	
)	
For: Rapid Absorption Selective 5-HT Agonist)	

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ELECTION

Sir:

In response to the Restriction Requirement mailed on June 1, 2007, Applicants elect with traverse the invention of Group I, claims 1-43 and 125-129. The traversal is on the basis that all of the groups include a pharmaceutical composition comprising a 5-HT antagonist, a spheronization aid and a solubility enhancer. Therefore, all groups are directed to related subject matter and should be examined together. At the least the Examiner should combine all the composition groups (Groups III through V) with Group I since the required searches for all of these groups should be substantially co-extensive.

As the species elections Applicants further elect sumatriptan from among the 5-HT antagonists recited in claim 5, glyceryl palmitostearate from the compounds recited in claim 10, macrogol fatty acid ester from the compounds recited in claim 16, and a fast-dispersing direct compression non-cushioning matrix tablet selected from among the formulations recited in claim 3 and 42. Applicants assume that the Election of Species Requirement is only for purposes of examination and that the Examiner will broaden the search to other species upon a determination that the elected subject matter is allowable.

If the Examiner has any questions concerning this Election or the application in general she is respectfully requested to contact the undersigned so that prosecution may be expedited.


Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: June 20, 2007

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)
RLT:sab

By:



Robin L. Teskin
Registration No. 35,030